

IPR & Innovation

1. [India to unveil new IPR policy in two months](#) – Mint

Regulatory & Medical

1. [Regulator to conduct surprise checks at drug manufacturing plants](#) – Hindustan Times
2. [Formation of National Regulator for Health Sector demanded](#) – Economic Times
3. [NGOs rake up demand for health regulator](#) – Millennium Post

Access to Healthcare

1. [Pharma cos demand raise in public spending on healthcare](#) – Moneycontrol.com
2. [Pharma industry demands increase in public spending on healthcare](#) – ET Health World
3. [Pharma Cos Demands Raise In Public Spending On Healthcare](#) – India Everyday
4. [Subir Gokarn: Health care - how, where & how much?](#) – Business Standard
5. [Pharmaceuticals demands increase in public spending on healthcare](#) – Medical Dialogues
6. [Pharma industry demands increase in public spending on healthcare](#) – Hindu Business Line
7. [Pharma industry demands increase in public spending on healthcare](#) – Economic Times
8. [Pharma firms want ObamaCare like health insurance in India](#) – Business Standard
9. [Hindustan Antibiotics, IDPL land to be sold for revival](#) – DNA
10. [Obamacare Architect On Hybrid Healthcare Financing For India](#) – Scrip Intelligence
11. [OPPI Fourth Healthcare Access Summit launch the paper on Healthcare Financing](#) – APN News
12. [Improving access to Healthcare in India Requires sustainable financing mechanisms & increased public spending on healthcare](#) – Instant Publish

Others

1. [EU says ban on GVK drugs is due to inaccurate data](#) – India Infoline
2. [Public health activists oppose move to introduce HPV vaccine in universal immunization](#) – Hindu Business Line
3. [Cry of the indigenous market](#) – Hindu Business Line
4. [Drug makers seek to shed their old skin](#) – Hindu Business Line

IPR & Innovation

1. [India to unveil new IPR policy in two months](#) – Mint
India is following rules related to intellectual property rights (IPR) and will unveil a new policy in two months, a government official said on Friday. Indian companies had done well in following IPR laws despite complaints from some quarters, said Amitabh Kant, secretary in the department of industrial policy and promotion (DIPP). Kant was speaking at the release of a report on the strategic rationale for deeper US-India economic ties where he noted that one of the irritants in the economic relationship between the two countries was India's perceived non-compliance with IPRs.

Regulatory & Medical

1. [Regulator to conduct surprise checks at drug manufacturing plants](#) – Hindustan Times
In the wake of the ban imposed by the European Union on 700 generic drugs, domestic pharma majors must now get ready for frequent surprise inspections and audit drives at their plants. "There should be no repeat of the clashes we had with US Food and Drug Administration. Though, we have stringent measures in place, we need to push firms for higher standards," GN Singh, Drug Controller General of India (DCGI), told HT.

2. [**Formation of National Regulator for Health Sector demanded**](#) – Economic Times
A group of NGOs today called for urgent creation of a National Regulator for Health Sector, which can become an effective tool for monitoring the delivery of healthcare services in an affordable manner to improve access to under-privileged sections of the society. According to a paper on 'Urgent need for Universal Health Coverage in the interest of Underprivileged Society of India' released today, to bring transparency and in current dismal scenario of primary health centres, this regulator should be empowered to take strong action against inefficient use of resources meant for healthcare and assure accessibility to the healthcare delivery system as per standards and existing laws.
3. [**NGOs rake up demand for health regulator**](#) –Millennium Post
Expressing dissatisfaction over accessibility of healthcare services and non-functioning of public health centres, civil societies have urged government to create national regulators for health sector on the lines of other regulators for food, telecom, drugs, among others. "An exclusive national regulator for healthcare sector should be set up, which can become an effective tool to monitor the delivery of healthcare services in an affordable manner to improve access to the underprivileged society in the country, Bejon Kumar Misra, who heads Consumer Online Foundation and PSM India Initiative said. Misra also said the health regulator, if created, would play a pivotal role in engaging with the private sector in managing the inefficient primary healthcare system in the country like it has already happened in a few states as pilot.

Access to Healthcare

1. [**Pharma cos demand raise in public spending on healthcare**](#) – Moneycontrol.com
As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'. "Investment in healthcare will contribute to economic development, through improved productivity, capital accumulation and reduced treatment burden," OPPI President, and Managing Director, India & Vice President, South Asia, Sanofi India Shailesh Ayyangar said at the fourth Healthcare Access Summit here, hosted by OPPI. Ranjana Smetacek, Director General, OPPI said "after decades of low public spending on healthcare, Government must now accord priority to this sector. A meaningful budget allocation will enable a healthcare model that delivers healthcare access for all."
2. [**Pharma industry demands increase in public spending on healthcare**](#) – ET Health World
Pharmaceutical industry today demanded increased public spending on healthcare to improve access to healthcare in the country. As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'.
3. [**Pharma Cos Demands Raise In Public Spending On Healthcare**](#) – India Everyday
As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled Healthcare Financing.
4. [**Subir Gokarn: Health care - how, where & how much?**](#) – Business Standard
In my previous column, I wrote about some patterns emerging from the National Sample Survey Office's (NSSO's) household survey on expenditure on education. The same round also queried expenditure on health by households. This column explores some findings from the 71st Round survey of social expenditures by households, carried out between January and June 2014.

The second relates to the social and economic costs of low access and inefficient delivery. In both the education and health domains, the consequences of inadequacy are felt over decades, even generations, and cannot be reversed in any significant measure. Whatever the legacy might be, it must remain a priority at all levels of government to find solutions that will provide widespread access and reasonable quality at reasonable cost.

5. [Pharmaceuticals demands increase in public spending on healthcare](#) – Medical Dialogues
Pharmaceutical industry today demanded increased public spending on healthcare to improve access to healthcare in the country.
As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'.
6. [Pharma industry demands increase in public spending on healthcare](#) – Hindu Business Line
Pharmaceutical industry on Friday demanded increased public spending on healthcare to improve access to healthcare in the country. As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'. The Centre is already seeking to overhaul the health system with an aim to advance universal health coverage and focus on social indicators of healthcare, it added.
7. [Pharma industry demands increase in public spending on healthcare](#) – Economic Times
"Investment in healthcare will contribute to economic development, through improved productivity, capital accumulation and reduced treatment burden," OPPI President, and Managing Director, India & Vice President, South Asia, Sanofi India Shailesh Ayyangar said at the fourth Healthcare Access Summit here, hosted by OPPI. Ranjana Smetacek, Director General, OPPI said "after decades of low public spending on healthcare, Government must now accord priority to this sector. A meaningful budget allocation will enable a healthcare model that delivers healthcare access for all."
8. [Pharma firms want ObamaCare like health insurance in India](#) – Business Standard
Pharmaceutical companies are making a pitch to Prime Minister Narendra Modi to subsidise health insurance with a view to make it universal. "We would like the government to provide health insurance on the lines of ObamaCare. Let the people pay for insurance. I am not saying the government pay for it. But today if one wants to avail health insurance it costs Rs Rs 4,000-5,000. Insurance companies will be able to offer cover at reduced premiums if they get aggregated demand or government gives a part subsidy. This way people in India can get quality health care," said Annaswamy Vaidheesh, GSK Pharmaceuticals' managing director in India.
9. [Hindustan Antibiotics, IDPL land to be sold for revival](#) – DNA
The government is looking to raise Rs 1,700 crore by monetising a part of land parcels owned by sick public sector pharma companies and using the proceeds for their revival. Ahir said his department is ready to offer help to pharma companies. "The commerce ministry plays an important role here. We will put forward our suggestions to the commerce ministry and we will also talk with the industry. We have made our medicines available in markets like the US and Europe which is an achievement. Now we shall ensure that this availability does not get impacted. But if the Indian companies are intentionally being targeted by the foreign countries, our government will look into it," he said. Meanwhile, the pharma companies are planning to submit a request to subsidising health insurance on the lines of ObamaCare in the US to Prime Minister Narendra Modi.

10. [Obamacare Architect On Hybrid Healthcare Financing For India](#) – Scrip Intelligence
Require Login to read the full article.
11. [OPPI Fourth Healthcare Access Summit launch the paper on Healthcare Financing](#) – APN News
Year after year, there have been advancements in the Healthcare Access Summit organized by the Organisation of Pharmaceutical Producers of India. Today, various stakeholders have a role in delivering quality healthcare in the country. There is a need to focus on a sustainable healthcare financing model which will help improve access to healthcare.
12. [Improving access to Healthcare in India Requires sustainable financing mechanisms & increased public spending on healthcare](#) – Instant Publish
The Organisation of Pharmaceutical Producers of India (OPPI) hosted its Fourth Healthcare Access Summit recently. This event built upon the themes of previous summits, bringing together policy-makers, leaders from the healthcare and pharmaceutical industries, healthcare experts and other distinguished professionals. Participants discussed diverse aspects of healthcare access and potential solutions.

Others

12. [EU says ban on GVK drugs is due to inaccurate data](#) – India Infoline
Regarding the ban imposed on some 700 drugs clinically tested by GVK Biosciences, the European Union (EU) clarified the move had neither to do with the efficiency of those drugs nor was it against the Indian pharmaceutical industry, according to reports. A report says that ban, was imposed due to "inaccurate data provided". The decision concerning a ban on 700 generic drugs was based on scientific - and not trade - considerations, and in accordance with the advice of the scientific committee of the EMA (European Medicines Agency), says report.
2. [Public health activists oppose move to introduce HPV vaccine in universal immunization](#) – Hindu Business Line
Public health, women rights organisations, researchers and doctors have submitted a memorandum to government, urging it to halt the reported move to introduce the human papillomavirus (HPV) vaccine in the universal immunisation programme. "We are extremely concerned about the long-term safety and efficacy of the HPV vaccines—Gardasil and Cervarix—and strongly feel that it would lead to serious adverse effects for its recipients," says a memorandum submitted to Health Minister J.P Nadda.
3. [Cry of the indigenous market](#) – Hindu Business Line
Self-sufficiency in manufacturing medical devices is critical to ensure affordable health care in India. But in this segment, India has not been able to replicate the success it achieved with pharmaceuticals. The Indian medical devices market is dominated by multinationals and the local demand is fulfilled substantially through imports especially in the case of high technology devices (about 80 percent), which constitutes about 68 percent of the total import of devices.
4. [Drug makers seek to shed their old skin](#) – Hindu Business Line
It was literally baptism by fire for Satish Reddy after he was appointed President of the Indian Pharmaceutical Alliance, representing the biggest boys of the domestic pharmaceutical industry. A revised regime on price control had just been introduced, casting its net over all 348 medicines on the Government's list of essential medicines. And the implementation of this Drug Prices Control Order (2013) had industry in a tizzy.